Skip to search formSkip to main contentSkip to account menu

GS-9669

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

FuransThiophenes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?
High sustained virologic response (SVR) rates have been observed after 6 weeks of anti-HCV treatment using sofosbuvir, ledipasvir… 
2016
2016
Ledipasvir/Sofosbuvir-Based Treatment of Patients with Chronic Genotype-1 HCV Infection and Cirrhosis: Results from Two Phase II Studies
Background Ledipasvir/sofosbuvir ± ribavirin administered for 12 weeks to patients with genotype-1 HCV infection and compensated… 
2015
2015
P0875 : Predictors of sustained viral response to 4–6 week duration therapy with ledipasvir + sofosbuvir + GS-9451 +/− GS-9669 in early and advanced fibrosis (NIH/UMD synergy trial)
Review
2014
Review
2014
GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection
Hepatitis C virus (HCV) is an RNA virus that chronically infects 2–3% of the world’s population. About 25% of these chronic… 
2014
2014
P1229 LOW PERSISTENCE OF RESISTANCE-ASSOCIATED VARIANTS AFTER 3 DAYS OF MONOTHERAPY WITH NS5B NNI SITE II INHIBITOR GS-9669 IN GENOTYPE 1 HCV PATIENTS
2014
2014
Lo mejor de la Asociación Americana para el Estudio de Enfermedades del Hígado
Autor de correspondencia: Dr. Vértiz 1147-201 Col. Narvarte CP 03100 México D.F. Teléfono: 52 5555391358. Correo electrónico… 
2014
2014
P1242 RESISTANCE ANALYSIS OF HCV GENOTYPE 1 INFECTED PATIENTS TREATED WITH SOFOSBUVIR IN COMBINATION WITH LEDIPASVIR OR THE NS5B NONNUCLEOSIDE INHIBITOR GS-9669: THE ELECTRON STUDY
2013
2013
1193 RESISTANCE ANALYSES USING DEEP AND POPULATION SEQUENCING AFTER 3 DAY MONOTHERAPY WITH GS-9669, A NOVEL NON-NUCLEOSIDE NS5B INHIBITOR IN GENOTYPE 1 HCV PATIENTS
2011
2011
1206 NONCLINICAL AND CROSS-GENOTYPIC PROFILES OF GS-9669, A NOVEL HCV NS5B NON-NUCLEOSIDE THUMB SITE II INHIBITOR
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)